CAR-NK cells: the next wave of cellular therapy for cancer

May Daher, Luciana Melo Garcia, Ye Li, Katayoun Rezvani

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations

Abstract

T cells engineered to express chimeric antigen receptors (CARs) have revolutionised the field of cellular therapy for cancer. Despite its success, this strategy has some recognised limitations and toxicities. Hence, there is growing interest in developing novel cellular therapies based on non-αβ T-cell immune effector cells, including NK cells that offer clear advantages in cancer immunotherapy. As a result, NK cells are being explored as an alternative platform for CAR engineering and are becoming recognised as important players in the next generation of cellular therapies targeting cancer. In this review, we highlight preclinical and clinical studies of CAR-NK cells derived from different sources and discuss strategies under investigation to enhance the antitumor activity of these engineered innate immune cells.

Original languageEnglish (US)
Article numbere1274
JournalClinical and Translational Immunology
Volume10
Issue number4
DOIs
StatePublished - 2021

Keywords

  • CAR
  • NK cells
  • allogeneic
  • cancer immunotherapy
  • cellular therapy
  • off-the-shelf product

ASJC Scopus subject areas

  • General Nursing
  • Immunology and Allergy
  • Immunology

Fingerprint

Dive into the research topics of 'CAR-NK cells: the next wave of cellular therapy for cancer'. Together they form a unique fingerprint.

Cite this